About Aspen Neuroscience
Aspen Neuroscience is a clinical-stage, private biotechnology company headquartered in San Diego, CA, developing personalized (autologous) iPSC-derived cell replacement therapies for Parkinson's disease and other CNS disorders. Its lead product, ANPD001 (sasineprocel), is derived from a patient's own skin cells reprogrammed into induced pluripotent stem cells and differentiated into dopaminergic neuronal precursor cells (DANPCs) for surgical transplantation. The therapy has received FDA Fast Track designation and is currently being evaluated in the ASPIRO Phase 1/2a clinical trial.
Company details
Funding
Total raised
$340M
Last stage
Series C
Investors
Founders
Jeanne Loring
World-renowned stem cell scientist whose groundbreaking research at the Scripps Research Institute formed the scientific foundation for Aspen Neuroscience's iPSC-derived dopaminergic neuron platform.
Andrés Bratt-Leal
Co-founder who served as a post-doctoral fellow in Jeanne Loring's lab and helped develop the core iPSC-to-dopaminergic neuron technology underlying Aspen. Holds a PhD in Biomedical Engineering from Georgia Tech.
Kim Kamdar
Co-founder of Aspen Neuroscience; also listed as a founder by multiple data sources including Tracxn.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.